A detailed history of Hexagon Capital Partners LLC transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Hexagon Capital Partners LLC holds 20 shares of NTLA stock, worth $286. This represents 0.0% of its overall portfolio holdings.

Number of Shares
20
Holding current value
$286
% of portfolio
0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 08, 2024

BUY
$19.72 - $27.36 $394 - $547
20 New
20 $0

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $1.09B
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Hexagon Capital Partners LLC Portfolio

Follow Hexagon Capital Partners LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hexagon Capital Partners LLC, based on Form 13F filings with the SEC.

News

Stay updated on Hexagon Capital Partners LLC with notifications on news.